|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ZC3H7B |
Gene summary for ZC3H7B |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ZC3H7B | Gene ID | 23264 |
| Gene name | zinc finger CCCH-type containing 7B | |
| Gene Alias | ROXAN1 | |
| Cytomap | 22q13.2 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q9UGR2 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 23264 | ZC3H7B | HTA11_1938_2000001011 | Human | Colorectum | AD | 2.41e-04 | 3.75e-01 | -0.0811 |
| 23264 | ZC3H7B | HTA11_347_2000001011 | Human | Colorectum | AD | 2.36e-08 | 3.93e-01 | -0.1954 |
| 23264 | ZC3H7B | HTA11_696_2000001011 | Human | Colorectum | AD | 7.55e-10 | 3.83e-01 | -0.1464 |
| 23264 | ZC3H7B | HTA11_866_2000001011 | Human | Colorectum | AD | 4.02e-03 | 1.98e-01 | -0.1001 |
| 23264 | ZC3H7B | HTA11_1391_2000001011 | Human | Colorectum | AD | 1.99e-07 | 5.88e-01 | -0.059 |
| 23264 | ZC3H7B | HTA11_866_3004761011 | Human | Colorectum | AD | 8.83e-08 | 4.33e-01 | 0.096 |
| 23264 | ZC3H7B | HTA11_7696_3000711011 | Human | Colorectum | AD | 1.77e-13 | 5.12e-01 | 0.0674 |
| 23264 | ZC3H7B | HTA11_99999970781_79442 | Human | Colorectum | MSS | 1.43e-04 | 3.46e-01 | 0.294 |
| 23264 | ZC3H7B | HTA11_99999971662_82457 | Human | Colorectum | MSS | 3.36e-21 | 7.20e-01 | 0.3859 |
| 23264 | ZC3H7B | HTA11_99999973899_84307 | Human | Colorectum | MSS | 1.76e-06 | 6.83e-01 | 0.2585 |
| 23264 | ZC3H7B | HTA11_99999974143_84620 | Human | Colorectum | MSS | 8.31e-05 | 3.41e-01 | 0.3005 |
| 23264 | ZC3H7B | A015-C-203 | Human | Colorectum | FAP | 1.31e-02 | -1.88e-01 | -0.1294 |
| 23264 | ZC3H7B | A001-C-108 | Human | Colorectum | FAP | 4.22e-02 | -1.98e-01 | -0.0272 |
| 23264 | ZC3H7B | A002-C-205 | Human | Colorectum | FAP | 5.78e-04 | -1.51e-01 | -0.1236 |
| 23264 | ZC3H7B | A002-C-114 | Human | Colorectum | FAP | 1.79e-03 | -2.18e-01 | -0.1561 |
| 23264 | ZC3H7B | A015-C-104 | Human | Colorectum | FAP | 5.65e-06 | -2.32e-01 | -0.1899 |
| 23264 | ZC3H7B | A002-C-016 | Human | Colorectum | FAP | 1.51e-05 | -2.08e-01 | 0.0521 |
| 23264 | ZC3H7B | A002-C-116 | Human | Colorectum | FAP | 1.50e-05 | -1.97e-01 | -0.0452 |
| 23264 | ZC3H7B | A018-E-020 | Human | Colorectum | FAP | 5.52e-03 | -1.65e-01 | -0.2034 |
| 23264 | ZC3H7B | F034 | Human | Colorectum | FAP | 4.02e-03 | -1.70e-01 | -0.0665 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0035196 | Colorectum | AD | production of miRNAs involved in gene silencing by miRNA | 20/3918 | 52/18723 | 2.87e-03 | 2.14e-02 | 20 |
| GO:0031050 | Colorectum | AD | dsRNA processing | 20/3918 | 54/18723 | 4.76e-03 | 3.22e-02 | 20 |
| GO:0070918 | Colorectum | AD | production of small RNA involved in gene silencing by RNA | 20/3918 | 54/18723 | 4.76e-03 | 3.22e-02 | 20 |
| GO:00351961 | Colorectum | MSS | production of miRNAs involved in gene silencing by miRNA | 19/3467 | 52/18723 | 1.66e-03 | 1.49e-02 | 19 |
| GO:00310501 | Colorectum | MSS | dsRNA processing | 19/3467 | 54/18723 | 2.74e-03 | 2.15e-02 | 19 |
| GO:00709181 | Colorectum | MSS | production of small RNA involved in gene silencing by RNA | 19/3467 | 54/18723 | 2.74e-03 | 2.15e-02 | 19 |
| GO:00351962 | Colorectum | FAP | production of miRNAs involved in gene silencing by miRNA | 19/2622 | 52/18723 | 4.16e-05 | 8.78e-04 | 19 |
| GO:00310502 | Colorectum | FAP | dsRNA processing | 19/2622 | 54/18723 | 7.56e-05 | 1.37e-03 | 19 |
| GO:00709182 | Colorectum | FAP | production of small RNA involved in gene silencing by RNA | 19/2622 | 54/18723 | 7.56e-05 | 1.37e-03 | 19 |
| GO:00351969 | Esophagus | ESCC | production of miRNAs involved in gene silencing by miRNA | 37/8552 | 52/18723 | 1.75e-04 | 1.14e-03 | 37 |
| GO:00310508 | Esophagus | ESCC | dsRNA processing | 38/8552 | 54/18723 | 2.08e-04 | 1.31e-03 | 38 |
| GO:00709188 | Esophagus | ESCC | production of small RNA involved in gene silencing by RNA | 38/8552 | 54/18723 | 2.08e-04 | 1.31e-03 | 38 |
| GO:00310507 | Oral cavity | OSCC | dsRNA processing | 31/7305 | 54/18723 | 4.66e-03 | 1.87e-02 | 31 |
| GO:00709187 | Oral cavity | OSCC | production of small RNA involved in gene silencing by RNA | 31/7305 | 54/18723 | 4.66e-03 | 1.87e-02 | 31 |
| GO:00351968 | Oral cavity | OSCC | production of miRNAs involved in gene silencing by miRNA | 30/7305 | 52/18723 | 4.84e-03 | 1.92e-02 | 30 |
| GO:003519616 | Thyroid | PTC | production of miRNAs involved in gene silencing by miRNA | 28/5968 | 52/18723 | 8.33e-04 | 5.13e-03 | 28 |
| GO:003105010 | Thyroid | PTC | dsRNA processing | 28/5968 | 54/18723 | 1.79e-03 | 9.68e-03 | 28 |
| GO:007091810 | Thyroid | PTC | production of small RNA involved in gene silencing by RNA | 28/5968 | 54/18723 | 1.79e-03 | 9.68e-03 | 28 |
| GO:003519617 | Thyroid | ATC | production of miRNAs involved in gene silencing by miRNA | 29/6293 | 52/18723 | 8.30e-04 | 4.57e-03 | 29 |
| GO:003105016 | Thyroid | ATC | dsRNA processing | 29/6293 | 54/18723 | 1.84e-03 | 9.03e-03 | 29 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ZC3H7B | SNV | Missense_Mutation | rs367879359 | c.371N>A | p.Arg124His | p.R124H | Q9UGR2 | protein_coding | deleterious(0.05) | possibly_damaging(0.725) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| ZC3H7B | SNV | Missense_Mutation | c.2446N>A | p.Glu816Lys | p.E816K | Q9UGR2 | protein_coding | deleterious(0.03) | benign(0.125) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| ZC3H7B | SNV | Missense_Mutation | c.2414G>C | p.Trp805Ser | p.W805S | Q9UGR2 | protein_coding | deleterious(0) | probably_damaging(0.962) | TCGA-BH-A18V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| ZC3H7B | SNV | Missense_Mutation | novel | c.2874N>G | p.Asp958Glu | p.D958E | Q9UGR2 | protein_coding | deleterious_low_confidence(0.03) | benign(0.038) | TCGA-C8-A3M7-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
| ZC3H7B | SNV | Missense_Mutation | c.2500G>A | p.Asp834Asn | p.D834N | Q9UGR2 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-EW-A1PD-01 | Breast | breast invasive carcinoma | Male | <65 | I/II | Chemotherapy | docetaxel | SD | |
| ZC3H7B | SNV | Missense_Mutation | novel | c.49N>T | p.Ile17Phe | p.I17F | Q9UGR2 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-OL-A66J-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| ZC3H7B | SNV | Missense_Mutation | novel | c.1058C>T | p.Pro353Leu | p.P353L | Q9UGR2 | protein_coding | tolerated(0.13) | benign(0.021) | TCGA-EA-A410-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| ZC3H7B | SNV | Missense_Mutation | c.2435N>A | p.Gly812Glu | p.G812E | Q9UGR2 | protein_coding | tolerated(0.58) | benign(0.06) | TCGA-EK-A2RB-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| ZC3H7B | SNV | Missense_Mutation | novel | c.1384N>A | p.Glu462Lys | p.E462K | Q9UGR2 | protein_coding | deleterious(0.03) | possibly_damaging(0.79) | TCGA-FU-A3NI-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| ZC3H7B | SNV | Missense_Mutation | c.1900N>T | p.Ala634Ser | p.A634S | Q9UGR2 | protein_coding | deleterious(0.02) | benign(0.33) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |